In 2020, Chen et al. demonstrated the efficacy of CRISPR-mediated genome editing in selectively targeting chronic myeloid leukemia (CML), a prevalent form of leukemia in adults characterized by the presence of the Philadelphia chromosome (Ph) and resulting BCR-ABL oncoprotein. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.